Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2549629rdf:typepubmed:Citationlld:pubmed
pubmed-article:2549629lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2549629lifeskim:mentionsumls-concept:C0543467lld:lifeskim
pubmed-article:2549629lifeskim:mentionsumls-concept:C0023884lld:lifeskim
pubmed-article:2549629lifeskim:mentionsumls-concept:C0005396lld:lifeskim
pubmed-article:2549629pubmed:issue3lld:pubmed
pubmed-article:2549629pubmed:dateCreated1989-10-11lld:pubmed
pubmed-article:2549629pubmed:abstractTextThe most effective surgical therapy of primary liver cancer (HCC) or proximal bile duct cancer (BDC) is radical resection, but only 20% of the patients will undergo this procedure, because the remaining patients in the advanced tumour-stage or cirrhosis can be given palliative treatment only (chemo-embolisation for HCC, endoscopic or percutaneous draining with or without iridium-after-loading for BDC) or a liver transplantation (LTX), though under immunosuppression an early recurrence of the tumour is frequent. One-year survival after resection because of HCC without cirrhosis is represented by a figure of 80%, whereas with cirrhosis it is 18%; 3 years after LTX, 26% of patients are alive. Three-year survival in untreated BDC is 24%, after resection of the hilum 42%, after LTX 40%.lld:pubmed
pubmed-article:2549629pubmed:languagegerlld:pubmed
pubmed-article:2549629pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2549629pubmed:citationSubsetIMlld:pubmed
pubmed-article:2549629pubmed:statusMEDLINElld:pubmed
pubmed-article:2549629pubmed:monthJunlld:pubmed
pubmed-article:2549629pubmed:issn0172-4614lld:pubmed
pubmed-article:2549629pubmed:authorpubmed-author:BeckerH DHDlld:pubmed
pubmed-article:2549629pubmed:authorpubmed-author:LauchartWWlld:pubmed
pubmed-article:2549629pubmed:authorpubmed-author:ViebahnRRlld:pubmed
pubmed-article:2549629pubmed:issnTypePrintlld:pubmed
pubmed-article:2549629pubmed:volume10lld:pubmed
pubmed-article:2549629pubmed:ownerNLMlld:pubmed
pubmed-article:2549629pubmed:authorsCompleteYlld:pubmed
pubmed-article:2549629pubmed:pagination119-22lld:pubmed
pubmed-article:2549629pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2549629pubmed:meshHeadingpubmed-meshheading:2549629-...lld:pubmed
pubmed-article:2549629pubmed:meshHeadingpubmed-meshheading:2549629-...lld:pubmed
pubmed-article:2549629pubmed:meshHeadingpubmed-meshheading:2549629-...lld:pubmed
pubmed-article:2549629pubmed:meshHeadingpubmed-meshheading:2549629-...lld:pubmed
pubmed-article:2549629pubmed:meshHeadingpubmed-meshheading:2549629-...lld:pubmed
pubmed-article:2549629pubmed:meshHeadingpubmed-meshheading:2549629-...lld:pubmed
pubmed-article:2549629pubmed:meshHeadingpubmed-meshheading:2549629-...lld:pubmed
pubmed-article:2549629pubmed:meshHeadingpubmed-meshheading:2549629-...lld:pubmed
pubmed-article:2549629pubmed:year1989lld:pubmed
pubmed-article:2549629pubmed:articleTitle[Surgical therapy of liver and bile duct tumors].lld:pubmed
pubmed-article:2549629pubmed:affiliationKlinik für Allgemeinchirurgie der Eberhard-Karls-Universität Tübingen.lld:pubmed
pubmed-article:2549629pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2549629pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:2549629pubmed:publicationTypeReviewlld:pubmed